Background {#Sec1}
==========

Fractures are an important public health burden. The age-standardized annual fracture incidence in England has been reported to be as high as 3.6% \[[@CR1]\] with great variation dependent on how and from which population it is estimated \[[@CR1]--[@CR3]\]. Years lived with disability due to fractures are estimated to be around 22 million, most of which are long-term disability \[[@CR4]\], and the total UK annual hospital costs associated with incident hip fractures in older adults alone are around £1.1 billion \[[@CR5]\].

Surgery is the preferred treatment of most displaced fractures, but evidence from recent years suggests that non-surgical treatment might serve as an effective alternative for selected fractures, potentially associated with fewer adverse events and lower costs \[[@CR6]--[@CR9]\].

Fractures of the clavicula, humerus, radius, ulna, metacarpals, femur, and ankle are some of the most common fractures \[[@CR2], [@CR3]\]. However, a comprehensive overview of the benefits (e.g., improvements in pain, function, and quality of life) and harms (e.g., serious adverse events) of surgical and non-surgical treatment of these and other fractures is missing. A better understanding of the benefits and harms of these treatments for each of the most common fractures separately would serve as an important basis for shared decision-making about treatment of fractures in clinical practice.

We therefore aimed in this systematic review and meta-analysis to determine the benefits and harms of surgical compared with non-surgical treatments for acute, traumatic, skeletal fractures in adults. We extend existing knowledge \[[@CR6]--[@CR9]\] by including more recent trials and by including and analyzing outcomes on patient-reported pain, physical function, quality of life, and SAE on each type of fracture separately.

Methods {#Sec2}
=======

This report conforms to the PRISMA statement \[[@CR10]\]. The study followed the published guidelines on systematic reviews from the Cochrane Collaboration \[[@CR11]\] and it was pre-registered with PROSPERO (CRD42015020805). In the PROSPERO-registration, two systematic reviews are described, the other being a systematic review of surgical vs. non-surgical treatment of non-fracture musculoskeletal conditions, which will be reported in a subsequent publication.

Search strategy {#Sec3}
---------------

Two authors (STS + CBT) searched MEDLINE via PubMed, EMBASE via Ovid, CINAHL (including preCINAHL) via EBSCO, Web of Science via Web of Knowledge and CENTRAL, all up to 5 November 2018. We included trials reported in English, German, Danish, Swedish, and Norwegian (i.e., languages that the authors understand). For SAEs, only trials enrolling patients from 2000 were included due to the increasing quality of surgery and anesthesia and with the expectation of improved reporting of SAEs following the CONSORT statement published in 1996 and updated in 2001. No time restriction was applied for benefits. The search strategies were adjusted according to the specifications of the individual database (see Additional file S[1](#MOESM1){ref-type="media"}). Reference lists of included articles and the most recent systematic reviews were reviewed to identify additional trials.

Trial selection {#Sec4}
---------------

Two authors (STS + CBJ) independently assessed titles/abstracts for trial eligibility using a priori selection criteria. The full text was retrieved if found eligible by at least one reviewer. The same authors independently evaluated eligibility of the retrieved full-text trials. Consensus was reached by discussion.

We included randomized trials conducted in any setting evaluating the effect of surgical treatment in comparison or in addition to non-surgical treatment of traumatic fractures in adults (mean age of trial participants 18+) with data on patient-reported pain, physical function, quality of life or SAEs. If any of these outcomes were reported, with data available that could be used in a meta-analysis, the trial was included. Surgery was pre-defined as any procedure that both changes the anatomy and requires a skin incision or use of an endoscopic technique \[[@CR12]\], while non-surgical treatment was defined as all non-surgical treatments and placebo treatments.

Trials investigating the effects of drug substances used perioperatively, vertebroplasty, and kyphoplasty, cancer-related fractures, and jaw fractures were excluded. Conference abstracts were also excluded.

Outcomes {#Sec5}
--------

Our pre-defined outcomes of interest for benefit were patient-reported pain, physical function, and quality of life, and SAEs for harm. If more than one outcome was available for patient-reported pain, physical function, and quality of life, multidimensional outcomes were preferred before unidimensional outcomes. For unidimensional pain, pain intensity in the activity was preferred over pain intensity in rest. We pre-defined SAEs using the U.S. Food and Drug Administration definition, as all adverse events having the potential to significantly compromise the clinical outcome, result in significant disability or incapacity, requiring inpatient or outpatient hospital care, and those considered to prolong hospital care, to be life-threatening, or to result in death \[[@CR13]\]. Non-unions were considered as SAE, while mal-unions were only considered as SAE if this resulted in additional treatment or significant disability or pain. Minor additional surgery such as removal of Kirschner wires was not considered an SAE, if they were part of normal clinical practice following the specific surgical procedure. Crossovers from non-surgical to surgical treatment were not considered an SAE unless caused by an SAE.

Data extraction {#Sec6}
---------------

A customized data extraction form was developed for the outcomes, and two authors (STS + CBJ) independently extracted data. We preferred data from the 12 months follow-up of the trials, as this is a very common primary endpoint in trials of orthopedic surgery and as benefits from surgical and non-surgical treatment are expected to be stable at that time point. If data was not available from a 12-month follow-up, data from the follow-up closest to 12 months was used. We extracted the number of patients randomized to each treatment, age, sex, study location (country), pain, and BMI at baseline, fracture type, surgical and non-surgical intervention, follow-up time, number of patients not undergoing surgery in the surgical group, number of crossover to surgical treatment, number of patients analyzed, mean effect and SD, deaths and SAEs during follow-up and types of SAEs. If SAEs, deaths, or crossover were not mentioned, it was considered as if it had not occurred.

Risk of bias assessment {#Sec7}
-----------------------

Risk of bias was assessed using the Risk of Bias 2.0 tool from the Cochrane Collaboration on trials with results on benefits \[[@CR14]\]. Two authors (STS + CBJ) independently assessed if each of the following five domains was associated with low risk of bias, some concerns or high risk of bias: (1) bias arising from the randomization process, (2) bias due to deviations from intended interventions, (3) bias due to missing outcome data, (4) bias in measurement of the outcome, (5) bias in selection of the reported result. If four or five of the individual domains were found to be associated with some concerns of risk of bias, or if one of them was associated with a high risk of bias, the overall risk of bias was rated as high risk.

For SAEs (including death) trial quality was assessed independently on trials with results on SAEs by two authors (STS + CBJ) using the 15-point McMaster tool for assessing quality of harms assessment and reporting in study reports (McHarm) \[[@CR15]\]. A score greater than 9 was considered a high score and indicative of low risk of bias.

Any discrepancies in the assessment of trial quality were resolved by discussion.

Data synthesis and statistical methods {#Sec8}
--------------------------------------

The benefits of surgery were estimated using meta-analyses as the standardized mean difference (SMD) allowing for pooling the various outcomes assessed in the individual trials. The SMD was estimated as the difference in mean at follow-up in the intervention and control groups divided by the pooled SD. If the SD was not available it was estimated from the standard error, confidence interval, or the *P* value, as recommended in the Cochrane Handbook \[[@CR11]\]. If necessary, means and measures of dispersion were estimated from figures in the included trials. If only SD of the baseline score and SD of the change score were available, these were used for estimating SD of the final score \[[@CR11]\]. SMD was adjusted to Hedges' g, as Cohen's d overestimate the effect in small studies. The SMD was interpreted clinically as originally proposed by Cohen \[[@CR16]\], i.e., a SMD of 0.2 was small, a SMD of 0.5 was moderate, and a SMD of 0.8 was large. Heterogeneity was estimated as between-study variance (tau^2^) and *I*-squared measuring the proportion of variation (i.e., inconsistency) in the combined estimates due to between-study variance. When *I*-squared is 0%, no inconsistency is seen between results of individual trials and inconsistency is maximal when *I*-squared is 100%.

SAEs were calculated as relative risk (RR). In order to handle null findings in either intervention or control group, Battaglias code was imputed. Battaglias code imputes one event distributed according to the numbers in the intervention and control group. The analyses of deaths followed the same approach. Results of individual studies were summed using a random-effects model meta-analysis for studies with relevant data on any of the outcomes, separated based on fracture type, body site, and outcome. While at least two studies were required to conduct meta-analyses on the different fracture types, all studies adhering to the eligibility criteria were included in the systematic review.

A *p* value less than 0.05 (two-sided) was considered significant. Analyses were carried out in Stata 15 (StataCorp, College Station, TX, USA).

Results {#Sec9}
=======

Description of included trials {#Sec10}
------------------------------

The literature search revealed 41,186 hits and 59 were identified from other sources (i.e., references in systematic reviews and in included studies). After removing duplicates, we screened 28,375 titles and abstracts, which led to the retrieval of 192 full texts. After screening full texts, we ended up with 61 trials (in 62 publications) with relevant data available on either patient-reported pain, function, quality of life, and/or SAEs (Fig. [1](#Fig1){ref-type="fig"}). These trials were spread across 19 fracture types at 13 body sites: calcaneal (displaced intra-articular), clavicula (displaced midshaft, other), femur (Pipkin type), humerus (proximal, shaft), malleolar (trimalleolar, unstable (uni- bi- or trimalleolar), stable lateral malleolar, other), metacarpal (5th), metatarsal (5th), radius (distal), rib (flail chest), scaphoid (waist), tibia (shaft), thoraco-lumbar spine (traumatic), ulnar (olecranon and shaft) fractures. Fig. 1Selection of trials of surgical and non-surgical treatment of fractures

Out of the 61 eligible trials (*n* = 6021 patients), 31 had data on pain (*n* = 2605), 45 on function (*n* = 3735), 18 on quality of life (*n* = 2306), 44 on SAEs (*n* = 3953), and 44 on deaths (*n* = 4145). Displaced midshaft clavicula (*n* = 14 trials), distal radius (*n* = 7), displaced intra-articular calcaneus (*n* = 6), scaphoid waist (*n* = 6), and proximal humerus (*n* = 6) fractures were the fractures most commonly investigated. Trials were carried out across 24 different countries, with the UK (*n* = 11), Sweden (*n* = 9), and the USA (*n* = 6) being the most common. Age and gender distribution varied depending on the fracture type. Table [1](#Tab1){ref-type="table"} presents the characteristics of the included trials. Table 1Summary of included trials of surgical and non-surgical treatment of fracturesFracture typeAuthor, year, countryAge, % femaleSurgical treatment (*n*)Did not undergo surgery after randomization (*n*)Non-surgical treatment (*n*)Received surgical treatment in control group (*n*)Benefit/harm outcomesFollow-up time (month)Calcaneal, displaced intraarticularAgren, 2013, Sweden \[[@CR17]\]48.5 years, 28.0%420400Pain, disability, QoL12 monthsBuckley, 2002 \[[@CR18]\] and O'Brien, Canada \[[@CR19]\]40.0 years, 10.3%20602180Pain, QoL24 monthsGriffin, 2014, UK \[[@CR20]\]46.4 years, 15.9%685753Disability, QoL SAE24 monthsIbrahim, 2007, UK \[[@CR21]\]48.5 years, 19.2%250310Pain, disability180 monthsNouraei, 2011, Iran \[[@CR22]\]49 years,360360Pain6 monthsThordarson, 1996, USA \[[@CR23]\]35.4 years, 19.2%160140Disability16 monthsClavicular, displaced midshaftAhrens, 2017, UK \[[@CR24]\]36.2 years, 13.6%1431113116Disability, SAE9 monthsChen, 2011c, China \[[@CR25]\]37.7 years, 46.7%300300Disability, SAE15 monthsJudd, 2009, USA \[[@CR26]\]26.5 years, 87.7%290280Disability, SAE12 monthsKoch, 2008, Germany \[[@CR27]\]35.4 years, 33.8%350330Pain, SAE1 monthKumar, 2018, India \[[@CR28]\]N/A400400SAE12 monthsMcKee, 2007, Canada \[[@CR29]\]33.5 years, 21.6%661641Disability, SAE12 monthsMelean, 2015, Chile \[[@CR30]\]37.6 years,340384SAE4 monthsMirzatolooei, 2011, Iran \[[@CR31]\]35.7 years, 18.0%293310Disability, SAE12 monthsQvist, 2018, Denmark \[[@CR32]\]39.5 years, 18.5%741669Disability, SAE12 monthsRobinson, 2013, UK \[[@CR33]\]32.4 years, 12.5%9509213Disability, QoL, SAE12 monthsSmekal, 2009, Austria \[[@CR34]\]37.7 years, 13.3%330323Disability, SAE6 monthsTamaoki, 2017, Brazil \[[@CR35]\]32.5 years, 14.5%590562Pain, disability, SAE12 monthsVirtanen, 2012, Finland \[[@CR36]\]36.7 years, 13.3%280311Pain, disability, SAE12 monthsWoltz, 2017, Netherlands \[[@CR37]\]37.8 years, 8.8%8606212Disability, QoL, SAE12 monthsClavicular, otherDugar, 2013, India \[[@CR38]\]N/A150150SAE12 monthsYadav, 2015, India \[[@CR39]\]33.1 years, 20.0%130120SAE3 monthsFemoral, caputChen, 2011a, China \[[@CR40]\]37.5 years, 18.8%8080SAE38 monthsChen, 2011b, China \[[@CR41]\]38.7 years, 29.2%120102SAE39 monthsHumeral shaftMatsunaga, 2017, Brazil \[[@CR42]\]38.7 years, 33.6%5201048Pain, disability, QoL, SAE12 monthsHumeral, proximalBoons, 2012, Netherlands \[[@CR43]\]78.2 years, 94.0%250250Pain, disability, SAE12 monthsFjalestad, 2014, Norway \[[@CR44]\]72.6 years, 88.0%250241Disability, QoL SAE12 monthsOlerud, 2011a, Sweden \[[@CR45]\]73.9 years, 81.4%270271Pain, Disability, QoL, SAE12 monthsOlerud, 2011b, Sweden \[[@CR46]\]76.7 years, 85.5%300300Pain, disability, QoL, SAE12 monthsRangan, 2015, UK \[[@CR47]\]66.0 years, 76.8%1091611213Disability, QoL, SAE12 monthsZyto, 1997, Sweden \[[@CR48]\]74.0 years, 87.5%200205Pain, disability50 monthsMalleolar, otherMakwana, 2001, UK \[[@CR49]\]66.9 years, 72.1%220148Pain, disability27 monthsWillet, 2016, UK \[[@CR50]\]70.6 years, 74.2%302727734Pain, disability, QoL, SAE6 monthsMalleolar, stableMittal, 2017, Australia and New Zealand \[[@CR51]\]39.0 years, 51.9%728782Disability, QoL, SAE12 monthsMalleolar, trimalleolarSalai, 2000, Israel \[[@CR52]\]78.3 years, 75.0%460830Pain, disability38 monthsMalleolar, unstableSanders, 2012, Canada \[[@CR53]\]41.0 years, 49.4%410391Disability, QoL, SAE12 monthsMetacarpal, 5th metacarpal neckSletten, 2015, Norway \[[@CR54]\]27.0 years, 82.3%384430Disability, SAE12 monthsStrub, 2010, Switzerland \[[@CR55]\]30.0 years, 5.0%200200SAE12 monthsMetatarsal, 5th metatarsal neckLee, 2016, South Korea \[[@CR56]\]41.7 years, 55.2%9090Pain2 monthsWu, 2018, China \[[@CR57]\]27.1 years, 36.6%230221Pain, SAE12 monthsRadial, distalAbbaszadegan, 1990, Sweden \[[@CR58]\]63.0 years, 76.6%230240Pain, disability12 monthsArora, 2011, Austria \[[@CR59]\]76.7 years, 75.3%450450Pain, disability, SAE12 monthsAzzopardi, 2005, UK \[[@CR60]\]71.5 years, 88.9%300270Pain, disability, QoL, SAE12 monthsFöldhazy, 2010, Sweden \[[@CR61]\]71.6 years, 89.8%280310Pain, disability, SAE12 monthsKreder, 2006, Canada and USA \[[@CR62]\]52.9 years, 65.5%540545Pain, disability12 monthsMardani Kivi, 2011, Iran \[[@CR63]\]50.8 years, 13.0%990936SAE3 monthsMcQueen, 2008, UK \[[@CR64]\]29.4 years, 16.7%300300SAE12 monthsWong, 2010, Hong Kong \[[@CR65]\]70.5 years, 81.7%310310Pain, disability, QoL, SAE12 monthsRib, flail chestMarasco, 2013, Australia \[[@CR66]\]58.5 years, 13.0%221230Pain, disability, QoL, SAE6 monthsScaphoid, waistArora, 2007, Austria \[[@CR67]\]33.0 years, 27.3%230240Pain, disability, SAE6 monthsClementson, 2015, Sweden \[[@CR68]\]31.4 years, 18.4%131240disability, SAE12 monthsDias, 2005, UK \[[@CR69]\]29.5 years, 10.2%440377Pain12 monthsVinnars, 2008, Sweden \[[@CR70]\]30.5 years, 22.7%403411Disability120 monthsThoraco-lumbal, traumatic compressionPiazzolla, 2011, Italy \[[@CR71]\]39.9 years, 36.0%240260Pain, disability, SAE12 monthsShen, 2001, Taiwan \[[@CR72]\]43.2 years, 48.8%337430Pain, disability12 monthsSiebenga, 2006, Netherlands \[[@CR73]\]41.8 years, 37.5%180160Pain, disability52 monthsWood, 2003, USA \[[@CR74]\]41.4 years, 31.9%260261Pain, disability, QoL46 monthsTibial shaftKarladani, 2000, Sweden \[[@CR75]\]39.0 years, 32.1%2701217Pain, Disability, QoL12 monthsGranetzny, 2005, Egypt \[[@CR76]\]38.2 years, 22.5%200200SAE2 monthsUlnar shaftHussain, 2018, India \[[@CR77]\]38.9 years, 13.3%200173Disability, SAE12 monthsUlnar, olecranonDuckworth, 2017, UK \[[@CR78]\]82.9 years, 89.5%11017Disability, SAE12 months*QoL* quality of life; *SAE* serious adverse events

As only one trial with relevant data was available for humeral shaft, malleolar (trimalleolar, unstable (uni- bi- or trimalleolar), stable lateral malleolar), tibia (shaft), and ulnar (olecranon and shaft) fractures, respectively, only 12 fracture types in 11 body sites were evaluated in meta-analyses. See Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, and [5](#Fig5){ref-type="fig"} for the number of trials and patients included in the meta-analyses within each of the fracture types for each of the outcomes. Fig. 2Results of the analysis of effects of surgical and non-surgical treatment on pain. Fracture sites are in alphabetic orderFig. 3Results of the analysis of effects of surgical and non-surgical treatment on function. Fracture sites are in alphabetic orderFig. 4Results of the analysis of effects of surgical and non-surgical treatment on quality of life. Fracture sites are in alphabetic orderFig. 5Results of the analysis of effects of surgical and non-surgical treatment on serious adverse events. Fracture sites are in alphabetic order

Benefits {#Sec11}
--------

### Synthesis of results {#Sec12}

The results of the meta-analytic syntheses for each of the fracture types separately are presented in Fig. [2](#Fig2){ref-type="fig"} (pain), Fig. [3](#Fig3){ref-type="fig"} (function), and in Fig. [4](#Fig4){ref-type="fig"} (quality of life).

For 6 out of the 8 fracture types with available data on pain, function, and quality of life from at least two trials, no important differences in pain and function were demonstrated between surgical and non-surgical treatment. No studies included a placebo treatment.

For 2 fracture types, surgical treatment was associated with greater benefits. For distal radius fractures (6 trial s\[[@CR58]--[@CR62], [@CR65]\] (*n* = 378)), the SMD was 0.31 (0.10 to 0.53) for function. For displaced intra-articular calcaneus fractures (4 \[[@CR17], [@CR20], [@CR21], [@CR23]\] /3 \[[@CR17], [@CR18], [@CR20]\] trials (*n* = 244/506), SMD was 0.64 (0.13 to 1.16) for function, and 0.19 (0.01 to 0.36) for quality of life.

Additional file S[2](#MOESM1){ref-type="media"} presents the full forest plots for all comparisons.

One trial on trimalleolar ankle fractures (*n* = 65) \[[@CR52]\] and one trial on tibial shaft fractures (*n* = 53) \[[@CR75]\] also demonstrated a significant effect for function in favor of surgery.

### Risk of bias {#Sec13}

Table [2](#Tab2){ref-type="table"} presents the risk of bias assessment for the individual trials. Table 2Assessment of risk of bias of included trials of surgical and non-surgical treatment of fracturesAuthor, yearRandomization processDeviations from intended interventionsMissing outcome dataMeasurement of the outcomeSelection of the reported resultOverall biasAbbaszadegan, 1990Some concernSome concernLow riskSome concernSome concernHigh riskAgren, 2013Low riskLow riskLow riskSome concernSome concernSome concernAhrens, 2017Low riskSome concernLow riskSome concernSome concernSome concernArora, 2007Some concernLow riskSome concernSome concernSome concernHigh riskArora, 2011Low riskLow riskLow riskSome concernSome concernSome concernAzzopardi, 2005Some concernLow riskSome concernSome concernSome concernHigh riskBoons, 2012Low riskLow riskLow riskSome concernSome concernSome concernBuckley, 2002Low riskLow riskHigh riskSome concernSome concernHigh riskChen, 2011cSome concernLow riskLow riskSome concernSome concernSome concernClementson, 2015Low riskSome concernHigh riskSome concernSome concernHigh riskDias, 2005Low riskLow riskSome concernSome concernSome concernSome concernDuckworth, 2017Low riskLow riskSome concernSome concernSome concernSome concernFjalestad, 2014Low riskLow riskLow riskSome concernSome concernSome concernFöldhazy, 2010Low riskSome concernSome concernSome concernSome concernHigh riskGriffin, 2014Low riskLow riskLow riskSome concernLow riskSome concernHussain, 2017Some concernSome concernSome concernSome concernSome concernHigh riskIbrahim, 2007High riskSome concernHigh riskSome concernSome concernHigh riskJudd, 2009Low riskLow riskSome concernSome concernSome concernSome concernKarladani, 2000Some concernHigh riskSome concernSome concernSome concernHigh riskKoch, 2008Some concernSome concernSome concernSome concernSome concernHigh riskKreder, 2006Low riskLow riskSome concernSome concernSome concernSome concernKumar, 2018High riskSome concernSome concernSome concernSome concernHigh riskLee, 2016Some concernSome concernLow riskSome concernSome concernHigh riskMakwana, 2001Low riskSome concernSome concernSome concernSome concernHigh riskMarasco, 2013Low riskLow riskLow riskSome concernSome concernSome concernMatsunaga, 2017Low riskSome concernSome concernSome concernLow riskSome concernMcKee, 2007Low riskLow riskSome concernSome concernSome concernSome concernMirzatolooei, 2011Low riskSome concernSome concernSome concernSome concernHigh riskMittal, 2017Low riskLow riskSome concernSome concernLow riskSome concernNouraei, 2011Some concernLow riskSome concernSome concernSome concernHigh riskOlerud, 2011aLow riskLow riskLow riskSome concernSome concernSome concernOlerud, 2011bLow riskLow riskLow riskSome concernSome concernSome concernPiazzolla, 2011Some concernLow riskLow riskSome concernSome concernSome concernQvist, 2018Low riskLow riskSome concernSome concernLow riskSome concernRangan, 2015Low riskSome concernLow riskSome concernLow riskSome concernRobinson, 2013Low riskSome concernLow riskSome concernSome concernSome concernSalai, 2000High riskHigh riskSome concernSome concernSome concernHigh riskSanders, 2012Low riskLow riskLow riskSome concernSome concernSome concernShen, 2001Some concernHigh riskSome concernSome concernSome concernHigh riskSiebenga, 2006Some concernLow riskLow riskSome concernSome concernSome concernSletten, 2015Low riskLow riskLow riskSome concernLow riskSome concernSmekal, 2009Low riskLow riskLow riskSome concernSome concernSome concernTamaoki, 2017Low riskLow riskSome concernSome concernSome concernSome concernThordarson, 1996Low riskLow riskSome concernSome concernSome concernSome concernVinnars, 2008Low riskLow riskLow riskSome concernSome concernSome concernVirtanen, 2012Low riskLow riskSome concernSome concernSome concernSome concernWillet, 2016Low riskLow riskLow riskSome concernLow riskSome concernWoltz, 2017Low riskSome concernSome concernSome concernLow riskSome concernWong, 2010Low riskLow riskSome concernSome concernSome concernSome concernWood, 2003Low riskLow riskSome concernSome concernSome concernSome concernWu, 2018Low riskLow riskLow riskSome concernSome concernSome concernZyto, 1997Low riskLow riskSome concernSome concernSome concernSome concernStudy quality was assessed for risk of bias using the Risk of Bias 2.0 tool from the Cochrane Collaboration on trials with results on patient-reported pain, physical function, and/or quality of life \[[@CR14]\]. If four or five of the individual domains was found to be associated with some concerns of risk of bias, or if one of them was associated with high risk of bias, the overall risk of bias was rated as high risk

Overall, no trials were judged as low risk of bias and 17 out of 52 trials \[[@CR18], [@CR21], [@CR22], [@CR27], [@CR28], [@CR31], [@CR49], [@CR52], [@CR56], [@CR58], [@CR60], [@CR61], [@CR67], [@CR72], [@CR75], [@CR77], [@CR79]\] were associated with a high risk of bias, mainly due to the lack of possibility to blind patients and treatment providers, and lack of pre-registration of the trial in a public trial registry before enrolment of the first patient.

Harms {#Sec14}
-----

### Synthesis of results {#Sec15}

The syntheses of the results are presented in Fig. [5](#Fig5){ref-type="fig"} (SAEs), and in Additional file S[2](#MOESM1){ref-type="media"} (deaths and the full forest plot for SAEs).

For 6 out of the 8 fracture types with available data on SAEs from at least two trials, no differences were demonstrated between surgical and non-surgical treatment. For displaced midshaft clavicula fractures (14 trial (*n* = 1394)) \[[@CR24]--[@CR37]\], surgery was associated with a smaller risk of SAEs than non-surgical treatment (RR 0.62 (0.42 to 0.92)). For distal radius fracture (5 trials (n = 436)) \[[@CR59]--[@CR61], [@CR65], [@CR80]\], surgery was associated with a greater risk of SAEs than non-surgical treatment (RR 3.10, 95% CI 1.42 to 6.77).

One trial on unstable malleolar fractures (*n* = 592) \[[@CR50]\] and one trial on humeral shaft fractures (*n* = 96) \[[@CR42]\] demonstrated fewer SAEs in the surgical compared to the non-surgical group.

There were no differences between surgical and non-surgical treatment in the risk of death for any of the fracture types.

### Risk of bias {#Sec16}

Additional file S[3](#MOESM1){ref-type="media"} presents the risk of bias assessment for the individual trials.

Overall, the risk of bias associated with the assessment and reporting of SAEs and death was moderate to high. Only two trials \[[@CR20], [@CR53]\] had a score greater than 9 indicating a low risk of bias.

Discussion {#Sec17}
==========

We found a difference in function in favor of surgery (moderate effect) for displaced intraarticular calcaneal fractures (however with large heterogeneity due to a small (*n* = 30), old study) and distal radial fractures (small effect), however, with increased risk of SAEs after surgery for radial fractures. No difference in effect was demonstrated for displaced midshaft clavicular fractures and proximal humeral fractures, scaphoid waist, and thoracolumbar traumatic compression fractures, while surgery for clavicular fractures was associated with reduced risk of SAE. Insufficient data existed for all other fracture types.

The large inconsistency and often missing reporting of SAEs and death in the included trials represent a limitation of our study. The lack of consensus in terms and definitions of complications after treatment of fractures calls for the development and validation of a core set of complications \[[@CR81]\]. Another potential limitation of this study relates to our selection of outcomes, as 39 trials were excluded due to insufficient data. Some of the trials had selected composite scores of, e.g., pain and function or other outcomes like time to healing of the fracture, while others did not report data that could be included in meta-analyses, e.g., by reporting pain evaluated on a 5-point Likert scale. For feasibility reasons, we excluded trials that were not in languages understood by any of the authors, which could be a potential bias. However, as only two trials were excluded based on this criterion, the expected impact on the results is considered minimal. Finally, from a clinical point of view, it is common to decide on whether to recommend surgery or not based not only on the fracture type, but also on patient characteristics such as age, work status, and symptom severity. In pragmatic trials, patients are more commonly included without accounting for patient characteristics, which thereby can potentially affect the generalizability of the results from the individual meta-analyses of this study \[[@CR63]\].

Although our results could indicate that non-surgical treatment is as effective as surgical treatment for several traumatic fractures in adults, including displaced midshaft clavicular, proximal humeral, scaphoid waist, and thoracolumbar traumatic compression fractures, serious caveats relating to the number of patients studied, heterogeneity and study methodology question the confidence in such a suggestion. First, only 7/19 fracture types had been scrutinized in at least 2 trials with at least 100 patients totally. Second, few and underpowered studies for some fracture types might be part of the explanation for our findings \[[@CR82]\], as a previous study found a mean overall study power (1-beta) among 117 trials of traumatic skeletal fractures of 25% \[[@CR83]\]. Third, none of the included trials were associated with a low risk of bias for benefits, and only 2/44 (5%) trials were associated with a low risk of bias for SAEs, confirming a previous study summarizing orthopedic trials \[[@CR82]\]. In fact, 17/52 (33%) of the trials with data on benefits were associated with a high risk of bias. Finally, the studied fracture types only represent selected types of fractures in selected types of patients. For some fractures (e.g., clavicular and stable lateral malleolar fractures), the natural history of healing without surgical treatment has a good prognosis \[[@CR84]--[@CR86]\]. However, in older persons with lower expectations of function with, e.g., a distal radius or malleolar fracture and more osteoporotic bone, the expected beneficial effect from surgical treatment is typically less than in younger more physically active patients. Thus, some of the studies included represent fracture types suspected to have limited benefits in terms of pain, function, and quality of life from surgical treatment. Other fracture types more obviously in need of surgery (displaced lower arm or hip fractures) is less likely to be subjected to randomization to non-surgical treatment; often termed parachute trials \[[@CR87]\]. Despite the mentioned limitations of the SAE reporting, some interesting findings are worth mentioning as our study presents the first overview of SAEs across RCTs of different fractures. While the risk of SAEs was lower from surgical treatment in displaced midshaft clavicular fracture, it was higher in distal radius fractures, and no difference was present for the other six comparisons with the estimated relative risk of SAEs distributed relatively even on both sides of the "no difference in risk" line, dependent on the fracture type. Importantly, most of the findings were based on 2-3 studies, including few patients, precluding any firm conclusions. However, our results do suggest that for some of the more often studied fracture types, like displaced midshaft clavicular fractures, distal radius fractures in older patients, proximal humerus fractures, and traumatic thoraco-lumbar compression fractures, non-surgical treatment might serve as an equally effective and safe treatment as surgical treatment.

Only 20% of the most commonly performed orthopedic procedures, including surgery for fractures, are supported by at least one low risk of bias trial \[[@CR88]\]. A search of trials of surgical and non-surgical treatment of fractures in the WHO International Clinical Trials Registry Platform \[[@CR89]\] indicates that several ongoing trials will provide data to help build the evidence base for optimal treatment of fractures. Our study is a call to action for more low-risk-of-bias trials powered to detect any difference in benefits and harms between surgical and non-surgical treatment of the most common traumatic skeletal fractures in adults. Although such studies are known to be challenging \[[@CR90]\], they are crucial to improve the clinical care of the patients.

Conclusion {#Sec18}
==========

Of 12 fracture types with data from more than one trial, only two demonstrated a difference in function in favor of surgery (moderate effect for displaced intraarticular calcaneal fractures, although affected by a large heterogeneity, and small effect for distal radial fractures), but with greater risk of harms after surgery for radial fractures. We found no difference in effect for displaced midshaft clavicular fractures, proximal humeral fractures, scaphoid waist, and thoracolumbar traumatic compression fractures, while surgery for clavicular fractures was associated with a reduced risk of SAE. Our results also highlight the current paucity of high-quality randomized trials for other common fracture types and a considerable heterogeneity for some of the estimates and risk of bias in a large proportion of available trials.
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